# Arcutis Biotherapeutics Inc. (ARQT)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $2.96B  
**Price:** $23.23 (+1.93%)

> Arcutis Biotherapeutics Inc. is a commercial-stage biopharmaceutical company specializing in medical dermatology treatments for immune-mediated skin diseases. It develops and commercializes innovative topical therapies, with its flagship product ZORYVE (roflumilast) available as a steroid-free cream and foam formulation. ZORYVE targets conditions such as plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, including approvals for various age groups like pediatrics. The company advances a broader immuno-dermatology pipeline, including Phase 2 trials for ZORYVE foam in vitiligo and hidradenitis suppurativa, and early development of ARQ-234, a CD200 receptor checkpoint agonist for atopic dermatitis. Arcutis Biotherapeutics Inc. focuses on regulatory expansions, clinical advancements, and commercial growth in the dermatology sector, addressing unmet needs in chronic inflammatory skin conditions through once-daily, leave-in applications that improve symptoms like itch and disease control.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $376M | $339M | -$12M | -$16M | — |
| 2024 | $197M | $177M | -$128M | -$140M | — |
| 2023 | $60M | $55M | -$241M | -$262M | — |
| 2022 | $4M | $3M | -$302M | -$311M | — |
| 2021 | — | — | -$207M | -$206M | — |
| 2020 | — | — | -$137M | -$136M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $433M | $243M | $189M | $43M | $109M |
| 2024 | $349M | $191M | $158M | $71M | $107M |
| 2023 | $341M | $253M | $89M | $88M | $202M |
| 2022 | $449M | $240M | $210M | $54M | $198M |
| 2021 | $408M | $110M | $298M | $96M | $72M |
| 2020 | $298M | $28M | $271M | $65M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$6M | $686,000 | -$6M |
| 2024 | -$112M | $143,000 | -$112M |
| 2023 | -$247M | $428,000 | -$247M |
| 2022 | -$258M | $333,000 | -$258M |
| 2021 | -$175M | $995,000 | -$176M |
| 2020 | -$113M | $321,000 | -$113M |
| 2019 | -$43M | $295,000 | -$43M |
| 2018 | -$14M | — | -$14M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ARQT)